---
schema_version: "secwatch.filing_event.v1"
accession: "0001410098-26-000044"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2026-08-07T20:18:31+00:00"
generated_at: "2026-08-07T20:19:05.313063+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CorMedix derivative suit settlement preliminarily approved; final hearing Sept 23, 2026

## Summary
- Court granted preliminary approval on July 24, 2026; final settlement hearing set for Sept 23, 2026 in Newark, NJ.
- Settlement requires corporate governance reforms maintained for 3.5 years; no monetary payment to stockholders.
- Plaintiffs' counsel may seek up to $3.9M in fees; defendants reserve right to oppose.
- Claims alleged fiduciary breaches over DefenCath manufacturing deficiencies and delayed FDA approval (2019-2022).
- Settlement resolves federal and state derivative actions; securities class action not part of this settlement.

## SEC filing metadata
- accession: 0001410098-26-000044
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2026-08-07T20:18:31+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000141009826000044/0001410098-26-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000141009826000044/crmd-20260807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001410098-26-000044
- JSON: https://secwatch.observer/filing/0001410098-26-000044.json
- Plain text: https://secwatch.observer/filing/0001410098-26-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.